Paper36966213
Intravenous Busulfan, Dimethylacetamide and neurotoxicity after high-dose pretransplant conditioning chemotherapy.
Ramdial J and 5 others. Bone Marrow Transplant, 2023. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Intravenous Busulfan, Dimethylacetamide and neurotoxicity after high-dose pretransplant conditioning chemotherapy. Papers, record 36966213. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36966213
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Intravenous Busulfan, Dimethylacetamide and neurotoxicity after high-dose pretransplant conditioning chemotherapy.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Busulfan | Major topic |
| Hematopoietic Stem Cell Transplantation | Major topic |
| Humans | |
| Acetamides | |
| Myeloablative Agonists | |
| Administration, Intravenous | |
| Transplantation Conditioning |
Source PubMed
References18
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12374454 | Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. | Biol Blood Marrow Transplant | 2002 | https://conductscience.org/library/papers/12374454 | PubMed |
| 2 | 29501779 | Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. | Biol Blood Marrow Transplant | 2018 | https://conductscience.org/library/papers/29501779 | PubMed |
| 3 | 1855615 | Developmental toxicity of dimethylacetamide by inhalation in the rat. | Fundam Appl Toxicol | 1991 | https://conductscience.org/library/papers/1855615 | PubMed |
| 4 | 23980086 | Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/23980086 | PubMed |
| 5 | 18489993 | Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. | Biol Blood Marrow Transplant | 2008 | https://conductscience.org/library/papers/18489993 | PubMed |
| 6 | 18215782 | High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. | Biol Blood Marrow Transplant | 2008 | https://conductscience.org/library/papers/18215782 | PubMed |
| 7 | 24065243 | Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. | Blood | 2013 | https://conductscience.org/library/papers/24065243 | PubMed |
| 8 | 14005853 | A phase I study of dimethylacetamide. | Cancer Chemother Rep | 1962 | https://conductscience.org/library/papers/14005853 | PubMed |
| 9 | 28522110 | High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. | Lancet Haematol | 2017 | https://conductscience.org/library/papers/28522110 | PubMed |
| 10 | 3321587 | Venoocclusive disease of the liver following bone marrow transplantation. | Transplantation | 1987 | https://conductscience.org/library/papers/3321587 | PubMed |
| 11 | 30910541 | Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. | Lancet Haematol | 2019 | https://conductscience.org/library/papers/30910541 | PubMed |
| 12 | 15073038 | Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. | Blood | 2004 | https://conductscience.org/library/papers/15073038 | PubMed |
| 13 | 8599861 | Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. | Cancer Chemother Pharmacol | 1996 | https://conductscience.org/library/papers/8599861 | PubMed |
| 14 | 24081656 | Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. | Blood | 2013 | https://conductscience.org/library/papers/24081656 | PubMed |
| 15 | 12374451 | Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. | Biol Blood Marrow Transplant | 2002 | https://conductscience.org/library/papers/12374451 | PubMed |
| 16 | 26071868 | Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. | Biol Blood Marrow Transplant | 2015 | https://conductscience.org/library/papers/26071868 | PubMed |
| 17 | 27991894 | Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. | Bone Marrow Transplant | 2017 | https://conductscience.org/library/papers/27991894 | PubMed |
| 18 | 6363247 | Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. | Hepatology | 1984 | https://conductscience.org/library/papers/6363247 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36966213
GET https://conductscience.org/api/papers/v1/36966213/authors